Abstract
It has been recognised that there is no need for phosphorous acid during the conversion of 1-heteroarylacetic acids to the corresponding dronic acids, as phosphorus trichloride (PCl3) is the real reagent. We could prove that the first intermediate toward the formation Risedronic acid is 3-pyridylacetyl chloride that was prepared in different ways using inorganic halides in toluene or in methanesulfonic acid (MSA). The intermediate was then reacted with two equivalents of PCl3 to afford risedronic acid after hydrolysis and pH adjustment. The pyridylacetyl chloride intermediate was identified on the basis of its esterification and amidation reaction. In MSA as the solvent, mixed anhydrides may also be formed as the intermediates from which the dronic acids may be formed in reaction with PCl3. A similar situation was anticipated for the reaction sequence of Zoledronic acid.
Keywords: Heteroarylacetic acid, Phosphorus trichloride, Heteroarylacetyl chloride, Alkyl heteroarylacetate, Heteroarylacetamide, Dronic acids, phosphorous acid, methanesulfonic acid (MSA), dronates, osteoporosis, Geminal bisphosphonates, hydroxy group, Alkyl Heteroarylacetates, pyridylacetyl chloride, Risedronic Acid, alkyl esters
Letters in Drug Design & Discovery
Title:Heteroarylacetyl Chlorides and Mixed Anhydrides as Intermediates in the Synthesis of Heterocyclic Dronic Acids
Volume: 9 Issue: 4
Author(s): Gyorgy Keglevich, Alajos Grun, Rita Kovacs, Katalin Koos, Beata Szolnoki, Sandor Garadnay, Jozsef Neu, Laszlo Drahos and Istvan Greiner
Affiliation:
Keywords: Heteroarylacetic acid, Phosphorus trichloride, Heteroarylacetyl chloride, Alkyl heteroarylacetate, Heteroarylacetamide, Dronic acids, phosphorous acid, methanesulfonic acid (MSA), dronates, osteoporosis, Geminal bisphosphonates, hydroxy group, Alkyl Heteroarylacetates, pyridylacetyl chloride, Risedronic Acid, alkyl esters
Abstract: It has been recognised that there is no need for phosphorous acid during the conversion of 1-heteroarylacetic acids to the corresponding dronic acids, as phosphorus trichloride (PCl3) is the real reagent. We could prove that the first intermediate toward the formation Risedronic acid is 3-pyridylacetyl chloride that was prepared in different ways using inorganic halides in toluene or in methanesulfonic acid (MSA). The intermediate was then reacted with two equivalents of PCl3 to afford risedronic acid after hydrolysis and pH adjustment. The pyridylacetyl chloride intermediate was identified on the basis of its esterification and amidation reaction. In MSA as the solvent, mixed anhydrides may also be formed as the intermediates from which the dronic acids may be formed in reaction with PCl3. A similar situation was anticipated for the reaction sequence of Zoledronic acid.
Export Options
About this article
Cite this article as:
Gyorgy Keglevich, Alajos Grun, Rita Kovacs, Katalin Koos, Beata Szolnoki, Sandor Garadnay, Jozsef Neu, Laszlo Drahos and Istvan Greiner , Heteroarylacetyl Chlorides and Mixed Anhydrides as Intermediates in the Synthesis of Heterocyclic Dronic Acids, Letters in Drug Design & Discovery 2012; 9 (4) . https://dx.doi.org/10.2174/157018012799859963
DOI https://dx.doi.org/10.2174/157018012799859963 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antifungal Agents in Hematopoietic Stem Cell Transplantation
Current Pharmaceutical Design Omega-3 Fatty Acids and their Role in Central Nervous System - A Review
Current Medicinal Chemistry Autoantibodies in Autoimmune Diseases
Current Pharmaceutical Design Smoking and Endothelial Progenitor Cells: A Revision of Literature
Current Pharmaceutical Design Inhibition of Membrane Fusion as a Target for Antiviral Therapy
Anti-Infective Agents in Medicinal Chemistry Orally Administrated Small Molecule Drugs with Intestine Targeted Profile: Recent Development and Prospects
Current Medicinal Chemistry Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Anti-Cancer Agents in Medicinal Chemistry Topotecan Is a Substrate for Multidrug Resistance Associated Protein 4
Current Drug Metabolism Medication Errors in Ambulatory Paediatric Patient Setting ‒ How Close, or Far, are we from an Error Free Process?
Infectious Disorders - Drug Targets Nonstandard Drugs and Feasible New Interventions for Autoimmune Hepatitis: Part II
Inflammation & Allergy - Drug Targets (Discontinued) Pharmacogenetics of Irinotecan Disposition and Toxicity: A Review
Current Clinical Pharmacology Drug-induced Cardiac Mitochondrial Toxicity and Protection: From Doxorubicin to Carvedilol
Current Pharmaceutical Design From Test Tube to Clinical Trial; Promising Herbs with NF-κB and COX- 2 Activity
Current Immunology Reviews (Discontinued) Development of Sendai Virus Vectors and their Potential Applications in Gene Therapy and Regenerative Medicine
Current Gene Therapy Clinical Trials in Children
Reviews on Recent Clinical Trials Prospects for Gene Therapy of Osteopetrosis
Current Gene Therapy Non Coding RNA in Muscle Differentiation and Disease
MicroRNA Carbohydrate based Potential Chemotherapeutic Agents: Recent Developments and their Scope in Future Drug Discovery
Mini-Reviews in Medicinal Chemistry The Pathogenic Subpopulation of Th17 Cells in Obesity
Current Pharmaceutical Design Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters